Bausch Health Projects 2026 Revenue Between $5.525B and $5.625B Amid Xifaxan Headwinds
Bausch Health Companies Inc. (BHC) reported a strong third quarter, marking its 14th consecutive quarter of year-over-year revenue and adjusted EBITDA growth when excluding Bausch + Lomb. CEO Thomas Appio highlighted the company's consistent performance despite upcoming challenges. Looking ahead, management provided long-term guidance projecting 2026 revenues to fall within the range of $5.525 billion to $5.625 billion. However, the company noted potential headwinds regarding Xifaxan in the fourth quarter, which may impact near-term growth trajectories.
Topics: adjusted EBITDA earnings report financial performance revenue growth